NCT04669587: ER+/HER2- Advanced or Metastatic Breast Cancer (ENZENO Study)

NCT04669587
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with any metastatic lesions that are ER negative
https://ClinicalTrials.gov/show/NCT04669587

Comments are closed.

Up ↑